Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review.
<h4>Objective</h4>To evaluate the efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis (AD), and provide reference for rational clinical medication.<h4>Methods</h4>PubMed, Medline, Embase, Web of Science, Clinical Trials Website, and Co...
Saved in:
Main Authors: | Dan-Jie Zhao, Xia Li, Hai-Xia Lin, Hong Zheng, Di Zhou, Peng Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0306463 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01) -
Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report
by: Katrina D Cirone, et al.
Published: (2025-02-01) -
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01) -
Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
by: Stamatios Gregoriou, et al.
Published: (2025-01-01) -
Allergen immunotherapy in atopic dermatitis
by: Agnieszka Bogacz-Piaseczyńska, et al.
Published: (2024-08-01)